login
login

Europe Daily Bulletin No. 12922

31 March 2022
Contents Publication in full By article 21 / 29
EU RESPONSE TO COVID-19 / Health
European Medicines Agency starts rolling review of SARS-CoV-2 vaccine developed by HIPRA
Brussels, 30/03/2022 (Agence Europe)

The European Medicines Agency (EMA) on 29 March 2022 initiated a rolling review process of PHH-1V, a vaccine against SARS-CoV-2 developed by the Spanish pharmaceutical company HIPRA.

The vaccine is intended to be administered intramuscularly as a booster dose in adults who have already completed a first vaccination schedule with another SARS-CoV-2 vaccine using a different technology.

PHH-1V is a recombinant protein vaccine. It contains two synthetic versions of fragments of the SARS-CoV-2...

Contents

SECTORAL POLICIES
Russian invasion of Ukraine
ECONOMY - FINANCE - BUSINESS
EXTERNAL ACTION
COURT OF JUSTICE OF THE EU
EU RESPONSE TO COVID-19
NEWS BRIEFS